Pierre Gholam, MD, associate professor of medicine at Case Western Reserve University School of Medicine, discusses his approach to recognizing and managing adverse events in patients receiving tyrosine kinase inhibitors for hepatocellular carcinoma.
Pierre Gholam, MD, observes the improvements in outcomes with lenvatinib seen in recent trials of unresectable hepatocellular carcinoma compared with the original phase 3 REFLECT trial.
Pierre Gholam, MD, examines the limited trial data on treatment for patients with hepatocellular carcinoma (HCC) with worse Child-Pugh scores.
During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, discussed the available therapy options for a patient with advanced hepatocellular carcinoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, discussed what role a biopsy and other procedures might serve in a patient with a LI-RADS 5 liver lesion. This is the first of 2 articles based on this event.
During a Targeted Oncology case-based roundtable event, Amit Singal, MD, and participants discussed the significance of LEAP-002 and other trials investigating immunotherapy plus tyrosine kinase inhibitor therapy in patients with hepatocellular carcinoma.
During a Targeted Oncology case-based roundtable event, Amit Singal, MD, discussed the data from the LEAP-002 trial of lenvatinib/pembrolizumab vs lenvatinib in patients with hepatocellular carcinoma.
During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discusses with participants the unexpected results of the LEAP-002 trial of lenvatinib plus pembrolizumab versus pembrolizumab alone for patients with hepatocellular carcinoma. This is the second of 2 articles based on this event.
During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.
During a live virtual event, Daneng Li, MD, discussed the case of a 77-year-old woman with stage IV hepatocellular cancer and a Child-Pugh score of A. This is the first of 2 articles from this event.
Pierre Gholam, MD, discussed with participants concerning the toxicity and management of lenvatinib for hepatocellular cancer and how it compares with sorafenib.
During a live virtual event, Pierre Gholam, MD, discussed treatment options for a patient with hepatocellular carcinoma who had serious medical conditions including cirrhosis, Crohn's disease, and variceal bleeding.
Daneng Li, MD, discusses the results of the REFLECT trial of lenvatinib in hepatocellular carcinoma.
During a live virtual event, Richard S. Finn, MD, discussed the process of selecting frontline treatment for hepatocellular carcinoma including liver and kidney transplants and immunotherapy agents.
During a live virtual event, Richard S. Finn, MD, discussed the process of diagnosing liver cancer after a CT scan detected tumors and whether a biopsy was needed.